Absorla Tablet (Apremilast)

Adult dose

The maintenance dose of this medication is 30 mg orally twice daily, approximately 12 hours apart. When restarting treatment after the initial administration, it may be administered without gradually increasing the dose. Table 1. Dosage and administration schedule for initial administration Day 1: 10 mg in the morning Day 2: 10 mg in the morning, 10 mg in the evening Day 3: 10 mg in the morning, 20 mg in the evening Day 4: 20 mg in the morning, 20 mg in the evening Day 5: 20 mg in the morning, 30 mg in the evening Day 6 onward: 30 mg in the morning, 30 mg in the evening No dosage adjustment is necessary for patients with mild or moderate renal impairment. Data in patients with moderate renal impairment are limited. For patients with severe renal impairment (creatinine clearance of 30ml/min or less, calculated using the Cockcroft-Gault equation), reduce the dose to 30 mg once daily. For initial administration in patients with severe renal impairment, gradual dose escalation is recommended using only the morning dose schedule specified in Table 1 and omitting the evening doses. No dosage adjustment is necessary for patients with hepatic impairment.

This medication should not be used in individuals who are allergic to this medication or its components, or in women who are pregnant or breastfeeding. Furthermore, it should not be administered to patients who are genetically unable to digest lactose. Caution is required when administering to patients with impaired renal function, and dosage adjustments may be necessary for patients with severe renal impairment. Gastrointestinal symptoms such as diarrhea, nausea, and vomiting are common when taking this medication, so patients should consult their doctor if symptoms are severe. Weight loss may occur, so regular weight monitoring is advised, and if unexplained weight loss occurs, medical consultation should be sought. Depression, mood changes, or suicidal thoughts may occur, so patients with a history of mental health issues should use with caution, and both patients and families should be vigilant for these symptoms. The effectiveness of this medication may be reduced when taken with certain potent medications, so be sure to inform your healthcare provider of any other medications being taken. Women planning pregnancy or with a possibility of becoming pregnant should consult with a healthcare provider before taking this medication, and it should be avoided during pregnancy. Breastfeeding women should avoid taking this medication, and its safety and efficacy in pediatric patients have not been established. No special dose adjustments are needed for the elderly, but care should be taken for any adverse reactions that occur. If any severe side effects or abnormal reactions occur while taking this medication, healthcare professionals should be notified immediately, and there may be a need to discontinue the medication. Keep out of reach of children, and store in the original container.

• Diarrhea
• nausea
• upper respiratory infection
• headache
• nasopharyngitis
• tension-type headache
• vomiting
• fatigue
• dyspepsia
• hypertension

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness and safety over time.

Appearance

10mg: Pink diamond-shaped film-coated tablet 20mg: Brown diamond-shaped film-coated tablet 30mg: Light brown diamond-shaped film-coated tablet

Package unit

Starter pack - 4 tablets/PTP [10mg], Starter pack - 4 tablets/PTP [20mg], Starter pack - 19 tablets/PTP [30mg], 30mg - 28 tablets/box [(14 tablets/PTP)x2], 30mg - 56 tablets/box [(14 tablets/PTP)x4]